At BIO 2026, where science meets real-world impact, you can access more than 135 sessions across 18 focus areas with discussions from leading biotechnology companies, investors, service providers, government officials, regulators and patient advocates.
Accelerate your career growth by adding a Professional Development Course to your BIO 2026 registration. Learn more.
We're sorry, but we couldn't find any results that match your search criteria. Please try again with different keywords or filters.
Loading
9:00 AM (PT)
-
Threats to U.S. national health security are becoming more frequent and complex, requiring stronger coordination between government and industry to improve detection capabilities, develop countermeasu ...Engagement Day 28ABCDE
1:00 PM (PT)
-
Company PresentationsCompany Presentations will take place in Theaters on the Exhibition Floor. Watch here for the detailed schedule, to be released in May. Find Presenting Companies in the Partnering system by filtering ...Company Presentation Session
1:45 PM (PT)
-
This session brings together leaders from pharma, AI technology, life sciences platforms, CROs, and specialized biotech AI to cut through the noise and examine how artificial intelligence is deliverin ...Breakout Session
-
AI and Digital Health
-
-
Within the Asia Pacific Region, Google Health and Health2Sync have partnered with Taiwan's National Health Insurance Administration and AI to stratify diabetes patients at risk of complications and th ...Breakout Session
- AI and Digital Health
Speakers -
-
The promise of cell and gene therapy is extraordinary - but so are the challenges of producing it at scale. Manufacturing remains the key barrier to delivering these life-changing therapies to patient ...Breakout Session
-
Biomanufacturing
-
-
Our industry has faced a variety of geopolitical and economic issues that inject uncertainty into deal-making. We must now navigate an unprecedented wave of legislation, executive orders, and policies ...Breakout Session
-
Business Development and Investment
Speakers -
-
Alzheimer’s disease is one of the greatest challenges facing patients, health systems, and society, affecting over 55 million people worldwide. At the intersection of a growing public health crisis, c ...Breakout Session
- Business Development and Investment
-
-
This intensive seminar provides biotech leadership teams with a practical, investor-facing playbook for raising institutional private capital. Designed for companies across stages, from early-stage pl ...Breakout Session
- Business Development and Investment
-
-
In vivo hematopoietic stem cell (HSC) engineering represents the next inflection point in genetic medicine - moving beyond transient delivery or ex vivo manipulation to direct, permanent reprogramming ...Breakout Session
-
Cell and Gene Therapy and Genome Editing
Speakers -
-
The healthcare ecosystem is experiencing an unprecedented transformation fueled by scientific, technological, geopolitical, economic, and demographic changes. Whilst breakthrough innovations are shapi ...Breakout Session
-
Emerging Opportunities in Global Markets
-
-
In recent years, the US public health apparatus has weathered mounting fiscal stress, shifting political priorities, and deep cuts at the federal level. Proposed reductions to the Centers for Disease ...Breakout Session
-
Infectious Disease and Vaccines
Speakers -
-
A longstanding priority for both Congress and FDA, there has been a significant evolution in recent years in the ways in which patients’ experiences and preferences have been incorporated into the dru ...Breakout Session
-
Orphan and Rare Disease
Speakers -
-
Despite growing calls for pediatric inclusion, many clinical trials, especially in rare diseases, continue to exclude children or delay their enrollment until late stages. Yet, in many rare diseases, ...Breakout Session
-
Science and Regulatory Innovation
Speakers -
-
Real world data (RWD) are increasingly relied upon to inform drug policy decisions at both the state and federal levels. For example, state Prescription Drug Affordability Boards (PDABs) are using all ...Breakout Session
-
Value, Patient Access and Reimbursement
-
)
)
)
)
)
)
)
.png/fit-in/120x9999/filters:no_upscale())
)
)
)
)
.jpg/fit-in/120x9999/filters:no_upscale())
)
)
)
)
)
)
)
)
)
)
)
.jpg/fit-in/120x9999/filters:no_upscale())
)
)
)
)
)
.jpg/fit-in/120x9999/filters:no_upscale())
)
)
.jpg/fit-in/64x9999/filters:no_upscale())
)
)
)
)
)
.jpg/fit-in/120x9999/filters:no_upscale())
)
)
)
)
)
2:00 PM (PT)
-
Storytelling StageThe BIO Storytelling Stage is a showcase of the heart of BIO's priorities—sharing the stories of the biotechnology industry that show who we are, who we serve, what we do, and why we do it. You'll hea ...Storytelling Stage Storytelling Stage (Booth #3035)Sponsored by:
3:00 PM (PT)
-
Generative genomics, using generative AI models to create entirely new, high-fidelity genomic data, represents a major shift in how we understand and apply biology. Large-scale AI models trained on ge ...Breakout Session
- AI and Digital Health
Speakers -
-
As technology evolves and AI requires more data to improve R&D productivity, the question largely becomes how much do we need versus how much do we want and subsequently, what are the unintended risks ...Breakout Session
- AI and Digital Health
ModeratorSpeakers -
-
The United States is making unprecedented investments to reshore biomanufacturing, strengthen supply chains, and enhance national security. As new facilities rise across the country, a critical questi ...Breakout Session
- Biomanufacturing
-
-
The financing and partnering environment for biotech has shifted significantly in recent years. Investors and partners have increasingly prioritized tangible, de-risked assets that offer compelling th ...Breakout Session
- Business Development and Investment
Moderator -
-
In biotech, success often hinges on spotting opportunities before anyone else does. Some of the industry’s most impactful companies have been built with smart business development regardless of their ...Breakout Session
- Business Development and Investment
Speakers -
-
When Emerging Biopharma (EBP) companies consider globalization, what criteria guide their choice of markets to enter? In Japan, the evaluation of innovative new drugs has advanced significantly, creat ...Breakout Session
- Emerging Opportunities in Global Markets
Speakers -
-
HBO Max’s “The Last of Us" captivated audiences with its gripping portrayal of a post-apocalyptic world ravaged by a fungal infection. While fictional, the threat posed by fungal pathogens is real. Fu ...Breakout Session
- Infectious Disease and Vaccines
-
-
For the first time in history, a patient has survived more than eight months following a gene-edited pig organ transplant, marking a pivotal moment as xenotransplantation moves from experimental promi ...Breakout Session
-
Next Generation Biotherapeutics
-
-
The biotech and pharmaceutical sectors are undergoing rapid transformation, driven by advances in digital health, artificial intelligence, personalized treatments, and cell and gene therapies. These b ...Breakout Session
- Science and Regulatory Innovation
Speakers -
-
Biomarker legislation is reshaping insurance and diagnostics policy across many US states, with more than 20 currently mandating coverage for biomarker testing under certain conditions. However, trans ...Breakout Session
- Value, Patient Access and Reimbursement
-
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
.jpg/fit-in/120x9999/filters:no_upscale())
)
)
)
)
)
)
)
.jpg/fit-in/120x9999/filters:no_upscale())
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
.jpg/fit-in/120x9999/filters:no_upscale())
)
3:15 PM (PT)
-
Europe offers a uniquely compelling platform for pharmaceutical growth. World class science, deep talent pools, and leading research infrastructures underpin continuous innovation across the value cha ...Breakout Session
- Business Development and Investment
-
)
4:15 PM (PT)
-
This session will explore how quantum computing is poised to redefine the frontiers of drug discovery by solving complex molecular and optimization problems that exceed the limits of classical computi ...Breakout Session
- AI and Digital Health
-
-
Clinical trials for large-population diseases face persistent challenges and remain the most complex and resource-intensive steps in drug development. Patient recruitment often lags, administrative bo ...Breakout Session
- AI and Digital Health
-
-
After two years of a quiet IPO window, the biotech markets are showing renewed signs of life. A growing number of companies are testing public waters again — but with tighter investor scrutiny, leaner ...Breakout Session
- Business Development and Investment
Speakers -
-
This session will feature a Fireside Chat with the former CEOand CBO of Capstan Therapeutics, as they share firsthand experience leading Capstan through one of the marquee M&A deals of 2025, a $2B+ ac ...Breakout Session
- Cell and Gene Therapy and Genome Editing
-
-
The China-US relationship will have a huge role in shaping the future of global biotech. Yet, this relationship is increasingly defined by both interdependence and tension — with science, supply chain ...Breakout Session
- Emerging Opportunities in Global Markets
Moderator -
-
Influenza has long served as the backbone for the United States’ annual respiratory disease response and pandemic preparedness efforts. Unfortunately, the flu continues to claim hundreds of thousands ...Breakout Session
- Infectious Disease and Vaccines
ModeratorSpeakers -
-
For decades, the biotech innovation engine has produced extraordinary breakthroughs in cancer, rare diseases, and metabolic disorders. Yet across vast areas of medicine from preeclampsia to sarcopenia ...Breakout Session
- Next Generation Biotherapeutics
-
-
As the biopharmaceutical industry strives to address areas of high unmet medical need, there is increasing reliance on novel endpoints to accelerate and support drug development. In rare diseases, tra ...Breakout Session
- Science and Regulatory Innovation
-
-
More than 10 million Americans live with osteoporosis. For decades, proving whether a new osteoporosis drug worked meant running massive clinical trials that followed thousands of people for 10–12 yea ...Breakout Session
-
Translational Research
Speakers -
-
There’s no question that drug development is a risky endeavor with scientific, clinical, and commercial risk. Patients and society value advances in science that help people get well, stay healthy, an ...Breakout Session
- Value, Patient Access and Reimbursement
-
)
)
)
)
)
)
)
.jpg/fit-in/120x9999/filters:no_upscale())
)
)
)
.png/fit-in/120x9999/filters:no_upscale())
)
)
)
)
)
.jpg/fit-in/120x9999/filters:no_upscale())
.jpeg.jpg/fit-in/64x9999/filters:no_upscale())
)
)
)
)
)
)
)
)
)
)
)
.jpg/fit-in/120x9999/filters:no_upscale())
)
)
)
)
)
)
)
)
9:00 AM (PT)
-
Gary Sinise, Actor-Humanitarian, and Founder of Gary Sinise Foundation, will be on the Main Stage on June 23, during "Driven by Purpose: Gary Sinise on Acting, Service, and Advocacy." In this featured ...Featured Program
-
Special Program
-
.jpg/fit-in/64x9999/filters:no_upscale())
)
10:00 AM (PT)
-
BioProcess International TheatreBioProcess International Theatre BioProcess Theatre
-
BioProcess Session BioProcess Theatre
-
• Contracting and Pricing • Demand Forecasting • Gross-to-Net • Pre-/Post- Deal Analysis • Accruals Management • Revenue ManagementBioProcess Session BioProcess Theatre
-
CDMO Capacity and Client Partnership Panel • How do you ensure your capacity planning aligns with actual client requirements rather than assumptions? • How do you balance multiple clients competing fo ...BioProcess Session BioProcess Theatre
-
)
)
10:30 AM (PT)
-
Company PresentationsCompany Presentations will take place in Theaters on the Exhibition Floor. Watch here for the detailed schedule, to be released in May. Find Presenting Companies in the Partnering system by filtering ...Company Presentation Session
11:00 AM (PT)
-
Storytelling StageThe BIO Storytelling Stage is a showcase of the heart of BIO's priorities—sharing the stories of the biotechnology industry that show who we are, who we serve, what we do, and why we do it. You'll hea ...Storytelling Stage Storytelling Stage - Booth 3035Sponsored by:
-
Storytelling Stage SessionStorytelling Stage Session Storytelling Stage (Booth #3035)
-
Storytelling Stage SessionStorytelling Stage Session Storytelling Stage (Booth #3035)
-
Storytelling Stage SessionStorytelling Stage Session Storytelling Stage - Booth 3035
-
Storytelling Stage SessionStorytelling Stage Session Storytelling Stage (Booth #3035)
-
Storytelling Stage SessionStorytelling Stage Session Storytelling Stage (Booth #3035)
-
Storytelling Stage SessionStorytelling Stage Session Storytelling Stage (Booth #3035)
-
Storytelling Stage SessionStorytelling Stage Session Storytelling Stage (Booth #3035)
-
Storytelling Stage SessionStorytelling Stage Session Storytelling Stage (Booth #3035)
-
Storytelling Stage SessionStorytelling Stage Session Storytelling Stage (Booth #3035)
-
-
The next evolution of AI in biopharma is already here - systems designed not just to analyze data but to make decisions. These “agentic AI” models can set goals, adapt strategies, and generate hypothe ...Breakout Session
- AI and Digital Health
ModeratorSpeakers -
-
This session will explore the critical journey of translating a scientific concept into a viable CNS therapeutic. Industry leaders will discuss the primary challenges and emerging solutions in neurosc ...Breakout Session
-
Brain Health
Speakers -
-
As the next wave of patent cliffs loom, the pressure is on pharma to secure late-stage assets that deliver near-term value. Meanwhile, biotech leaders are navigating tighter capital markets and evolvi ...Breakout Session
- Business Development and Investment
ModeratorSpeakers -
-
As major patent expirations loom, pricing pressures intensify and R&D productivity comes under strain, large pharmaceutical companies are accelerating dealmaking to fill therapeutic and clinical-stage ...Breakout Session
- Business Development and Investment
Moderator -
-
AI has generated substantial interest across the life sciences industry, yet its practical adoption in commercial forecasting and early asset assessments remains limited. Many organizations continue t ...Breakout Session
- Business Development and Investment
Sponsored by:
-
-
Messenger RNA (mRNA) medicines are increasingly recognized for their transformative power to improve patient health, as well as a strategic asset with implications for national and global security. Th ...Breakout Session
- Infectious Disease and Vaccines
-
-
Healthcare providers are often faced with the same set of challenges when diagnosing women with Alzheimer’s – debunking the stigma that has shaped the Alzheimer’s narrative for women and their familie ...Breakout Session
-
Patient Advocacy
-
-
Europe is actively working to improve the clinical research environment, with particular emphasis on supporting biotechnology innovation and adapting to evolving scientific and societal needs. As new ...Breakout Session
- Science and Regulatory Innovation
ModeratorSpeakers -
-
Kickstart your journey in biotechnology by exploring the industry’s vast landscape and discovering where your skills and interests can make an impact. Experts will provide an overview of biotech acros ...Breakout Session
- Special Program
-
-
The life sciences industry is built on innovation and driven by purpose. As competing for talent and earning public trust become critical business drivers, leading life sciences companies are investin ...Breakout Session
-
Workforce, Health Equity, and Leadership
-
)
)
)
)
)
.jpg/fit-in/64x9999/filters:no_upscale())
)
)
)
)
)
)
)
)
)
)
)
)
)
)
.jpg/fit-in/120x9999/filters:no_upscale())
)
)
.jpg/fit-in/120x9999/filters:no_upscale())
)
)
)
)
)
.jpg/fit-in/120x9999/filters:no_upscale())
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
12:15 PM (PT)
-
Super SessionThe biopharma industry has reached a critical inflection point. While pioneering new scientific frontiers, the industry faces challenges from global budgetary pressures and, in the U.S., structural di ...Super Session 28ABCDESponsored by:
.jpg/fit-in/120x9999/filters:no_upscale())
)
1:45 PM (PT)
-
AI is redefining what’s possible across industries, and nowhere is the opportunity greater than in life sciences. But unlocking its full power requires more than algorithms — it demands bold new ways ...Breakout Session
- AI and Digital Health
-
-
Central Nervous System (CNS) disorders remain among the most complex and urgent challenges in global healthcare. This session will spotlight the latest advancements in CNS research and development, hi ...Breakout Session
- Brain Health
Speakers -
-
Macroeconomic challenges that have hindered biotech IPO activity are subsiding and capital markets are expected to improve later in 2026, especially for early-stage biotech companies. Increased M&A ac ...Breakout Session
- Business Development and Investment
Speakers -
-
This data-driven session from BIO and its market intelligence partner, Norstella, will dive into the state of play for emerging biotech companies. From venture capital and public financing, deal-makin ...Breakout Session
- Business Development and Investment
-
-
This session will explore how pharma/biotech companies achieve pipeline diversity through portfolio strategy, strategic collaborations, and scientific rigor. The conversation will examine the processe ...Breakout Session
- Business Development and Investment
-
-
Rare diseases collectively affect more than 300 million people worldwide, yet fewer than 5% have an approved treatment. As cell and gene therapies (CGTs) progress from scientific aspiration to commerc ...Breakout Session
- Cell and Gene Therapy and Genome Editing
-
-
Precision medicine has transformed oncology, but the next wave is unfolding in new therapeutic areas. The expansion into new areas promises enormous impact, yet the path forward is not straightforward ...Breakout Session
-
Diagnostics and Personalized Medicine
Speakers -
-
Clinical trials in small populations, particularly those with progressive or degenerative rare diseases, face scientific and ethical hurdles that challenge traditional trial frameworks. High phenotypi ...Breakout Session
- Orphan and Rare Disease
Speakers -
-
Recent changes in FDA’s leadership and approach have caused some concern among industry leaders and patients about the stability, predictability, and reliability of our regulatory framework. While our ...Breakout Session
- Science and Regulatory Innovation
Speakers -
-
Nearly a year ago, the One Big Beautiful Bill became law and states immediately felt the implications of its sweeping health care provisions. This session will provide a cross-stakeholder view on how ...Breakout Session
- Value, Patient Access and Reimbursement
Sponsored by:
-
)
)
)
)
)
)
.jpg/fit-in/120x9999/filters:no_upscale())
)
)
)
)
)
)
)
)
.jpg/fit-in/120x9999/filters:no_upscale())
)
)
)
)
)
)
)
)
)
)
)
)
.jpg/fit-in/64x9999/filters:no_upscale())
)
)
)
)
)
)
2:40 PM (PT)
-
BioProcess International TheatreBioProcess International Theatre BioProcess Theatre
-
What manufacturing innovations have delivered the most significant cost reductions while maintaining product quality in your biologics operations? How are you balancing the capital investment required ...BioProcess Session BioProcess Theatre
-
3:00 PM (PT)
-
AI is becoming ubiquitous in biopharma, but no company can unlock its full potential alone. As the industry shifts from "tell me" to "show me," the pressure is on to move beyond the hype and use AI to ...Breakout Session
- AI and Digital Health
Sponsored by:
-
-
AI-enabled discovery and multimodal, human-centric datasets are reshaping how biopharma and digital health companies differentiate, partner, and scale. Rather than focusing on capital trends, this ses ...Breakout Session
- AI and Digital Health
-
-
Novel manufacturing technologies can help rapidly scale manufacturing capabilities, increase supply chain resilience, bring manufacturing closer to the patient, and support greener manufacturing. On a ...Breakout Session
- Biomanufacturing
-
-
Women’s health is now a dynamic arena for innovation, data science, and strategic capital deployment. This session brings together leading investors to discuss where smart capital is flowing and how s ...Breakout Session
- Business Development and Investment
-
-
As life sciences innovation becomes increasingly global, many emerging biotech ecosystems continue to face barriers to accessing the capital, infrastructure, and networks that define established hubs ...Breakout Session
- Business Development and Investment
-
-
Intelligence Precision Medicine cannot achieve its promise if entire populations remain underrepresented in the data that fuels it. As multiomic and real-world datasets expand, the next wave of therap ...Breakout Session
- Diagnostics and Personalized Medicine
Speakers -
-
This session explores how patient preference studies (PPS) are transforming regulatory strategies in drug development, aligning with the upcoming ICH E22 guideline - the first international guideline ...Breakout Session
- Science and Regulatory Innovation
Speakers -
-
Clinical trials have too often failed to represent the communities they aim to serve - limiting the relevance, reach, and real‑world impact of medical innovation. The Robert A. Winn Excellence in Clin ...Breakout Session
- Workforce, Health Equity, and Leadership
Speakers -
)
)
)
)
)
)
)
)
)
)
)
.jpg/fit-in/64x9999/filters:no_upscale())
)
)
)
)
)
)
)
)
)
)
)
)
.jpg/fit-in/120x9999/filters:no_upscale())
)
4:15 PM (PT)
-
Cancer immunotherapy has transformed oncology, yet many patients still don't respond or develop resistance to these treatments. Meanwhile, AI has generated unprecedented libraries of potential targets ...Breakout Session
- AI and Digital Health
-
-
For years, therapeutic development for Alzheimer’s and other neurodegenerative diseases has focused on the pathologies within the brain such as, in the case of Alzheimer’s, amyloid plaques and tau tan ...Breakout Session
- Brain Health
-
-
AI-enabled discovery and multi-modal, human-centric datasets are driving the next wave of biopharma partnerships. Collaborations are expanding rapidly, characterized by larger upfronts, equity-linked ...Breakout Session
- Business Development and Investment
Speakers -
-
Patients are in urgent need of breakthrough treatments, and the global community benefits most when America drives the next generation of biotechnology innovations. However, America’s leadership is in ...Breakout Session
- Business Development and Investment
-
-
With federal agencies commitments being uncertain and wavering, many researchers as well as emerging drug and device developers are struggling to find funding or to continue projects. At the same time ...Breakout Session
- Business Development and Investment
Moderator -
-
The metabolic disease treatment landscape is transforming rapidly. While GLP-1 receptor agonists have demonstrated remarkable efficacy, addressing the full scope of metabolic dysfunction requires ther ...Breakout Session
- Next Generation Biotherapeutics
-
-
Congress created the Rare Pediatric Disease Priority Review Voucher (PRV) program to incentivize the development of drugs for serious or life-threatening rare diseases in children. Vouchers are earned ...Breakout Session
- Orphan and Rare Disease
Speakers -
-
The landmark ORPHAN Cures Act has catalyzed investment in rare disease research since its passage last year, bringing hope to millions of patients and their families. Early data demonstrates renewed p ...Breakout Session
- Orphan and Rare Disease
Sponsored by:
-
-
We are living in a golden age of biopharmaceutical innovation. Yet, too often, patients face barriers between them and the appropriate treatment they need across various cost-shifting programs. Payers ...Breakout Session
- Patient Advocacy
-
-
HHS secretary mandates NIH and FDA federal agencies to implement immediately the FDA Modernization Act which aims to establish a new roadmap to reduce animal testing in preclinical safety studies. Suc ...Breakout Session
- Translational Research
Speakers -
-
As we approach 50 years of biotechnology innovation, a generation of female leaders are reshaping the industry at some of the most influential companies in biopharma, including as CEOs of Vertex and A ...Breakout Session
- Workforce, Health Equity, and Leadership
-
)
.jpg/fit-in/120x9999/filters:no_upscale())
)
.png/fit-in/120x9999/filters:no_upscale())
)
)
)
)
)
)
)
)
)
)
)
.jpg/fit-in/120x9999/filters:no_upscale())
)
)
)
.jpg/fit-in/64x9999/filters:no_upscale())
)
)
)
)
)
)
)
.jpg/fit-in/120x9999/filters:no_upscale())
)
)
)
)
)
)
)
)
)
)
)
)
9:00 AM (PT)
-
This year, Genentech celebrates its 50th anniversary—a milestone that marks not only the founding of the company, but the birth of the biotechnology industry itself. To mark this moment, join a dynami ...Featured Program Main StageSponsored by:
.jpg/fit-in/64x9999/filters:no_upscale())
)
)
9:30 AM (PT)
-
BioProcess International TheatreBioProcess International Theatre BioProcess Theatre
-
BioProcess Session BioProcess Theatre
-
BioProcess Session BioProcess Theatre
-
• Contracting and Pricing • Demand Forecasting • Gross-to-Net • Pre-/Post- Deal Analysis • Accruals Management • Revenue ManagementBioProcess Session BioProcess Theatre
-
BioProcess Session BioProcess Theatre
-
CDMO Capacity and Client Partnership Panel • How do you ensure your capacity planning aligns with actual client requirements rather than assumptions? • How do you balance multiple clients competing fo ...BioProcess Session BioProcess Theatre
-
BioProcess Session BioProcess Theatre
-
As biopharmaceutical pipelines grow increasingly diverse — encompassing monoclonal antibodies, recombinant proteins, gene therapies, cell therapies, and other novel modalities — the pressure to stream ...BioProcess Session BioProcess Theatre
-
What manufacturing innovations have delivered the most significant cost reductions while maintaining product quality in your biologics operations? How are you balancing the capital investment required ...BioProcess Session BioProcess Theatre
-
)
)
)
10:30 AM (PT)
-
Company PresentationsCompany Presentations will take place in Theaters on the Exhibition Floor. Watch here for the detailed schedule, to be released in May. Find Presenting Companies in the Partnering system by filtering ...Company Presentation Session
11:00 AM (PT)
-
Storytelling StageThe BIO Storytelling Stage is a showcase of the heart of BIO's priorities—sharing the stories of the biotechnology industry that show who we are, who we serve, what we do, and why we do it. You'll hea ...Storytelling Stage Storytelling Stage - Booth 3035Sponsored by:
-
AI has moved from concept to execution in drug discovery, but turning algorithms into actionable insights requires deep scientific alignment and cross-functional integration. This session brings toget ...Breakout Session
- AI and Digital Health
Speakers -
-
The biomanufacturing workforce challenge is not national - it is global. No single country or stakeholder can solve it alone. The National Institute for Bioprocessing Research and Training (NIBRT) Pro ...Breakout Session
- Biomanufacturing
Speakers -
-
The 36th edition of EY’s Beyond Borders Biotechnology Report provides an in-depth look at the US and European biotech industry as the operating and regulatory ecosystem is undergoing dramatic changes. ...Breakout Session
- Business Development and Investment
Speakers -
-
As the global biotech ecosystem becomes increasingly interconnected, in-licensing has evolved into a core growth engine, with US–Asia deal-making and NewCo formation continuing to accelerate as compan ...Breakout Session
- Business Development and Investment
Speakers -
-
As diagnostics and precision medicine continue to advance, companies developing novel diagnostic technologies, analytical tools, and data-enabled testing solutions are reshaping how disease is detecte ...Breakout Session
- Diagnostics and Personalized Medicine
-
-
The role of vaccines in preventing and eradicating numerous infectious diseases is unparalleled; however, the past year has presented some new challenges for the industry, calling into question the sc ...Breakout Session
- Infectious Disease and Vaccines
Speakers -
-
Overall survival (OS) remains the gold standard endpoint in oncology trials, but the FDA’s August 2025 draft guidance highlights new complexities in assessing survival in an era of highly effective th ...Breakout Session
-
Oncology
-
-
As the life sciences industry continues its expansion, the demand for highly skilled talent frequently outpaces local supply. Solving this bottleneck requires more than isolated efforts; it demands a ...Breakout Session
- Special Program
-
-
This session is designed to provide students with the guidance and connections needed to enter the world of biotechnology after receiving their degree. Panelists will share their personal career journ ...Breakout Session
- Special Program
-
-
New Approach Methodologies (NAMs) are playing an increasingly central role in biomedical and life-science research, while also breaking scientific and regulatory boundaries by moving beyond early adop ...Breakout Session
- Translational Research
Speakers -
)
)
.jpeg)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
.jpg/fit-in/120x9999/filters:no_upscale())
)
11:30 AM (PT)
-
BioProcess International Theatre
1:40 PM (PT)
-
BioProcess International TheatreBioProcess International Theatre BioProcess Theatre
-
BioProcess Session BioProcess Theatre
-
As biopharmaceutical pipelines grow increasingly diverse — encompassing monoclonal antibodies, recombinant proteins, gene therapies, cell therapies, and other novel modalities — the pressure to stream ...BioProcess Session BioProcess Theatre
-
1:45 PM (PT)
-
Although artificial intelligence (AI) has existed for decades, recent advances in computational power, data availability, and machine learning models have significantly accelerated its development and ...Breakout Session
- AI and Digital Health
-
-
For centuries, nature, and particularly the innate immune system, has encoded powerful mechanisms for disease control and repair. Today, artificial intelligence (AI) is reshaping drug discovery by rev ...Breakout Session
- AI and Digital Health
-
-
In recent years, a confluence of global economic, market, and policy shifts have led to the abandonment of more than 1,000 promising treatments in development for rare diseases - many of which deliver ...Breakout Session
- Business Development and Investment
-
-
This session will explore ARPA-H’s unique SBIR/STTR funding opportunities and the distinctive commercialization support designed to propel breakthrough companies forward. Attendees will hear firsthand ...Breakout Session
- Business Development and Investment
Moderator -
-
This session focuses on shifting from reactive to preventative strategies in managing medicine shortages. Speakers will highlight supply chain resilience, harmonized processes and systems, and innovat ...Breakout Session
- Emerging Opportunities in Global Markets
Speakers -
-
Both Secretary Kennedy and Commissioner Makary have signaled that there will be a new era of “radical transparency” at the Food and Drug Administration (FDA). Regulatory transparency is generally desi ...Breakout Session
-
Intellectual Property and Legal Landscape
-
-
Longevity science has entered its execution era. What once sounded speculative now rests on clearer biology, richer human datasets, and maturing toolkits that are pushing longevity from buzzword to bu ...Breakout Session
- Next Generation Biotherapeutics
-
-
Oncology continues to be the leading therapeutic area across the biopharma industry by almost all measures, including global drug sales, number of pipeline programs, venture capital dollar deployment, ...Breakout Session
- Oncology
Speakers -
-
The April 2025 Food and Drug Administration Roadmap to Reducing Animal Testing in Preclinical Safety Studies is a signature effort to shift the prevailing drug development paradigm. Aiming to reduce c ...Breakout Session
- Science and Regulatory Innovation
Speakers -
-
The biopharmaceutical industry needs sources for more, and better prepared talent, and there is building enthusiasm for skills-based hiring. Over the past few years, the Registered Apprenticeship (RA) ...Breakout Session
- Workforce, Health Equity, and Leadership
Speakers -
)
)
.jpg/fit-in/120x9999/filters:no_upscale())
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
.jpg/fit-in/64x9999/filters:no_upscale())
)
)
)
)
)
)
)
)
)
.jpg/fit-in/120x9999/filters:no_upscale())
3:00 PM (PT)
-
The biotech ecosystem is navigating real headwinds — tighter capital, increasingly complex science, and an increasingly unforgiving path from discovery to clinic. But pressure also creates openings. T ...Breakout Session 29ABSponsored by:Eli Lilly
-
AI technologies are no longer a peripheral concept in drug discovery – these platforms are a driving force for innovative companies reshaping the way we identify targets, and design, optimize, and val ...Breakout Session
- AI and Digital Health
-
-
Until recently, drug discovery has been limited by fundamental practical constraints such as the range of proteins that exist in nature or the availability of samples, time, and funding for experiment ...Breakout Session
- AI and Digital Health
-
-
Biomanufacturing is at an inflection point. From the outside‑in, macro forces - significant near‑shoring investments over the next 3–5 years, costing pressures, and the need for regional, resilient su ...Breakout Session
- Biomanufacturing
-
-
This panel discussion addresses a critical paradox in biotechnology investment - while female-founded biotech’s demonstrate superior returns, they receive less than 3% of venture funding. This session ...Breakout Session
- Business Development and Investment
-
-
Inherited Retinal Diseases (IRDs) were once considered untreatable, leaving patients and families facing the certainty of progressive vision loss. Today, advances in gene therapy are changing that rea ...Breakout Session
- Cell and Gene Therapy and Genome Editing
-
-
As pricing pressures mount in the US, pharmaceutical companies are reassessing global launch strategies. This session looks to explore how geopolitical shifts - including US policy changes, EU pharmac ...Breakout Session
- Intellectual Property and Legal Landscape
ModeratorSpeakers -
-
For decades, autoimmune disease therapy has been defined by one trade-off - suppressing the immune system to relieve symptoms. That paradigm is now breaking. The 2025 Nobel Prize in Physiology of Medi ...Breakout Session
- Next Generation Biotherapeutics
-
-
For 87 years, our industry had to operate under an uncomfortable truth: over 90% of cancer drugs that "cure" mice routinely fail patients in clinical trials. In 2022, the FDA Modernization Act 2.0 too ...Breakout Session
- Oncology
Speakers -
-
The 340B program was initially intended to help safety net hospitals further serve vulnerable communities. However, the program has now ballooned into a massive profit generator for hospitals that oft ...Breakout Session
- Patient Advocacy
-
)
.jpg/fit-in/64x9999/filters:no_upscale())
)
)
.jpg/fit-in/120x9999/filters:no_upscale())
)
)
)
)
)
)
)
)
.png/fit-in/120x9999/filters:no_upscale())
.png/fit-in/64x9999/filters:no_upscale())
)
)
)
)
)
)
)
)
)
)
)
)
.jpg/fit-in/120x9999/filters:no_upscale())
)
)
)
)
)
)
4:15 PM (PT)
-
Death of expertise in the dawn of AI has been vastly overreported with no sign of its ability to displace creative and disciplined drug discovery teams. Citing Bernstein Research, the Financial Times ...Breakout Session
- AI and Digital Health
-
-
Artificial intelligence (AI) has become a widely used label across biotech companies positioning platforms for drug discovery and development. However, what truly defines an AI-marketed platform today ...Breakout Session
- AI and Digital Health
Speakers -
-
Europe's decades-long decline in pharmaceutical R&D and delay in patient access to medicines are the direct result of government policies designed to lower spending on innovative medicines, including ...Breakout Session
- Business Development and Investment
Moderator -
-
Back by popular demand, this session returns with fresh insights for 2026. Health and science executives will learn how to build and deliver an investor-ready story using LaVoieHealthScience’s LHS Fif ...Breakout Session
- Business Development and Investment
-
-
Long-term post-marketing safety monitoring is crucial for understanding the risks of new therapies in real-world settings, yet current registries often create considerable burdens without delivering r ...Breakout Session
- Cell and Gene Therapy and Genome Editing
Speakers -
-
The FDA’s new guidance supporting non-animal testing methods is reshaping preclinical drug development, creating unprecedented opportunities for biotech innovation. This session brings together biotec ...Breakout Session
- Next Generation Biotherapeutics
-
-
Heart disease remains the leading cause of death in the United States, with a person dying every 34 seconds from cardiovascular disease, claiming almost one million American lives every year and accou ...Breakout Session
- Next Generation Biotherapeutics
Speakers -
-
The advances in technology over the past decade have yielded a broad range of biologics for cancer, each with unique attributes. This is great news for patients to have so many tools in the toolkit, b ...Breakout Session
- Oncology
-
-
Venture capital funding specifically for women’s health biotech and pharmaceuticals has undergone a significant transformation since 2023. While the broader "Women's Health" category is often dominate ...Breakout Session
- Patient Advocacy
-
-
Enacted in 1992, the Prescription Drug User Fee Act (PDUFA) establishes how regulated industry fees support the human drug review program at the Food and Drug Administration (FDA) and associated Agenc ...Breakout Session
- Science and Regulatory Innovation
-
)
)
)
.jpg/fit-in/64x9999/filters:no_upscale())
)
.png/fit-in/120x9999/filters:no_upscale())
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
.jpg/fit-in/64x9999/filters:no_upscale())
)
)
)
)
9:00 AM (PT)
-
In an increasingly selective capital environment, a handful of biotech CEOs have managed to defy the odds—closing $100 million-plus financing rounds that fueled major growth, platform expansion, and p ...Breakout Session
- Business Development and Investment
-
-
CAR-T cell therapy has fundamentally transformed outcomes for patients with certain hematologic malignancies and, increasingly, solid tumors — yet the vast majority of eligible patients never receive ...Breakout Session
- Cell and Gene Therapy and Genome Editing
-
-
The biopharmaceutical industry faces persistent misinformation campaigns targeting patent practices, with myths about patent thickets, evergreening, and excessive patent filings driving misguided poli ...Breakout Session
- Intellectual Property and Legal Landscape
-
-
Long before immunotherapy took center stage, it lived on the margins of oncology. Those pursuing it were often politely dismissed as “dreamers,” relegated to the back rooms at ASCO as well-intentioned ...Breakout Session
- Oncology
Speakers -
-
Even though orphan drugs currently account for almost 50% of all new medicine approved in USA and EU, many conditions still lack therapeutic options, and it has been estimated that 90-95% of the more ...Breakout Session
- Orphan and Rare Disease
Speakers -
-
Colorado offers a collaborative environment for life sciences where companies, researchers, and partners work together, accelerating discoveries that save and change patient lives. In this interactive ...Breakout Session
- Patient Advocacy
Speakers -
-
This session brings together leaders from early-to-late-stage biotech’s and the investment community to explore practical frameworks for transforming early-stage discoveries into development-ready the ...Breakout Session
- Translational Research
Speakers -
)
.jpg/fit-in/120x9999/filters:no_upscale())
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
.jpg/fit-in/120x9999/filters:no_upscale())
)
)
)
10:00 AM (PT)
-
Company PresentationsCompany Presentations will take place in Theaters on the Exhibition Floor. Watch here for the detailed schedule, to be released in May. Find Presenting Companies in the Partnering system by filtering ...Company Presentation Session
10:15 AM (PT)
-
Cell and gene therapies have become invaluable modalities in the medicine toolkit. Following recent safety concerns with AAV vector technology, experts will look increasingly toward new vectors and de ...Breakout Session
- Cell and Gene Therapy and Genome Editing
Moderator -
-
Europe is taking bold steps in transforming its biotech industry, from strengthening biotech ecosystems, simplifying regulatory framework, and accelerating trial authorizations, to creating better fun ...Breakout Session
- Emerging Opportunities in Global Markets
Speakers -
-
Intellectual property rights remain the foundation of innovation in the life sciences. Today, that foundation is facing sustained and coordinated pressure from all sides. Insurers, pharmacy benefit ma ...Breakout Session
- Intellectual Property and Legal Landscape
Moderator -
-
Since the first drugs were selected for “negotiation,” the Inflation Reduction Act (IRA) has been the target of litigation. Two strains of litigation emerged, with one focusing on the constitutionalit ...Breakout Session
- Intellectual Property and Legal Landscape
-
-
Antibody–drug conjugates (ADCs) reshaped cancer treatment by combining the precision of targeted antibodies with the potency of cytotoxic therapies, but as the field matures, the focus is shifting tow ...Breakout Session
- Oncology
-
-
Sponsors routinely collect patient experience data (PED) to better understand disease areas and ensure development programs meet patient needs. To advance patient-focused drug development effectively, ...Breakout Session
- Science and Regulatory Innovation
-
-
The path from academic discovery to patient impact has never been more complex. Federal funding shifts, market turbulence, and evolving expectations for commercialization are challenging traditional m ...Breakout Session
- Translational Research
Speakers -
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
){kind=logo}